SCHEMBL1789849

SCHEMBL1789849

CNCCc1ccc(Nc2nccc(-c3c(-c4cccc(NC(=O)c5c(F)cccc5F)c4)nc4ccccn34)n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 15/20 0.70
BRAF P15056 3/20 0.70
EGFR P00533 5/20 0.66
ERBB2 P04626 5/20 0.66
SLC2A1 P11166 1/20 0.58
INSR P06213 2/20 0.56
CDK19 Q9BWU1 2/20 0.56
PRKD3 O94806 2/20 0.56
MAP4K4 O95819 2/20 0.56
LCK P06239 2/20 0.56
FYN P06241 2/20 0.56
CSF1R P07333 2/20 0.56
RET P07949 2/20 0.56
MET P08581 2/20 0.56
ROS1 P08922 2/20 0.56
FLT1 P17948 2/20 0.56
KDR P35968 2/20 0.56
MAP4K2 Q12851 2/20 0.56
STK3 Q13188 2/20 0.56
ROCK1 Q13464 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791633 0.92 IGF1R (0.67) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1788599 0.91 IGF1R (0.79) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1788026 0.90 IGF1R (0.65) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1786177 0.90 IGF1R (0.66) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1785764 0.89 IGF1R (0.67) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1787431 0.89 BRAF (0.60) IGF1RBRAFEGFRERBB2INSR
SCHEMBL1789490 0.89 IGF1R (0.70) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1790729 0.88 IGF1R (0.80) IGF1RBRAFEGFRERBB2SLC2A1
SCHEMBL1791360 0.88 EGFR (0.63) IGF1RBRAFEGFRERBB2INSR
SCHEMBL1786627 0.87 IGF1R (0.59) IGF1RBRAFEGFRERBB2INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 IGF1R 937/4885BRAF 226/4885EGFR 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.